Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors inside the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7